Byungwoo Ryu, PhD
Adjunct Assistant Professor
Boston University School of Medicine
Dept of Dermatology

PhD, Oregon State University
MS, Chonbuk National University



Dr. Ryu joined the Department of Dermatology at the Boston University of School of Medicine as an assistant Professor in 2011. He received his Ph.D. degree from Oregon State University in Molecular Toxicology. Dr. Ryu completed his postdoctoral fellowships at the National Cancer Institute in Bethesda, Maryland and Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University School of Medicine, Baltimore, Maryland. Dr. Ryu served as an assistant member of the Nevada Cancer Institute at Las Vegas, Nevada and clinical assistant professor of medicine at the University of Nevada School of Medicine at Reno, Nevada. Dr. Ryu is a recipient of Howard Temin Award, career development award (K01), from the National Cancer Institute.

Dr. Ryu’s research interest is to determine the molecular events that dictate melanoma tumorigenicity and malignant progression. It is likely that identification of such molecular pathways will allow us to identify clinically useful biomarkers as well as potential therapeutic targets against this lethal form of skin cancer.

Biomarkers for melanoma progression: Dr. Ryu’s laboratory currently focuses on discovery of molecular biomarkers that can be used for patient stratification and personalized therapy. His laboratory uses genomic and molecular profiling techniques on tissue and blood samples from melanoma patients to find patterns of molecular signatures and correlate them with clinical outcomes.

Therapeutic targeting of metastasis-initiating cells (MICs): Despite recent progress, the molecular mechanisms of tumor metastasis remain unclear. Isolation and dissection of the MICs, subpopulation of tumor cells including circulating cancer cells in patient’s blood, will shed light on the molecular events of metastasis progression. Dr. Ryu’s laboratory focuses on the genetic and epigenetic characterization of the MICs as well as developing therapeutic and preventive strategies of cancer metastasis by targeting the MICs.

Assistant Professor
Boston University School of Medicine
Pathology & Laboratory Medicine




TARGETING TRANSCRIPTIONAL CO-REPRESSOR COREST COMPLEX IN MELANOMA
09/01/2017 - 05/31/2018 (PI)
NIH/National Cancer Institute
1R01CA212639-01A1

EPIGENETIC DETECTION AND CHEMOPREVENTION OF SKIN CANCER
10/01/2015 - 06/30/2016 (PI)
Johns Hopkins University V Foundation

MELANOMA ASSAYS BASED ON NRP-2
05/01/2010 - 09/30/2015 (Co-PI)
PI: Rhoda Alani, MD
Laboratory Corporation of America

DEVELOPMENT OF NOVEL MARKERS FOR MELANOMA PROGRESSION
10/01/2011 - 06/30/2012 (PI)
NIH/National Institutes of Health
7K01CA113779-07




Yr Title Project-Sub Proj Pubs
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Eisenstein A, Panova IP, Chung HJ, Goldberg LJ, Zhang Q, Lazova R, Bhawan J, Busam KJ, Symanowski JT, Alani RM, Ryu B. Quantitative assessment of neuropilin-2 as a simple and sensitive diagnostic assay for spitzoid melanocytic lesions. Melanoma Res. 2018 Feb; 28(1):71-75.View Related Profiles. PMID: 29227334.
     
  2. Kalin JH, Wu M, Gomez AV, Song Y, Das J, Hayward D, Adejola N, Wu M, Panova I, Chung HJ, Kim E, Roberts HJ, Roberts JM, Prusevich P, Jeliazkov JR, Roy Burman SS, Fairall L, Milano C, Eroglu A, Proby CM, Dinkova-Kostova AT, Hancock WW, Gray JJ, Bradner JE, Valente S, Mai A, Anders NM, Rudek MA, Hu Y, Ryu B, Schwabe JWR, Mattevi A, Alani RM, Cole PA. Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. Nat Commun. 2018 01 04; 9(1):53.View Related Profiles. PMID: 29302039.
     
  3. Hsu MY, Yang MH, Schnegg CI, Hwang S, Ryu B, Alani RM. Notch3 signaling-mediated melanoma-endothelial crosstalk regulates melanoma stem-like cell homeostasis and niche morphogenesis. Lab Invest. 2017 Jun; 97(6):725-736.View Related Profiles. PMID: 28165469; DOI: 10.1038/labinvest.2017.1;.
     
  4. Hwang S, Kim HE, Min M, Raghunathan R, Panova IP, Munshi R, Ryu B. Epigenetic Silencing of SPINT2 Promotes Cancer Cell Motility via HGF-MET Pathway Activation in Melanoma. J Invest Dermatol. 2015 Sep; 135(9):2283-91.View Related Profiles. PMID: 25910030; PMCID: PMC4537358; DOI: 10.1038/jid.2015.160;.
     
  5. Rossi M, Tuck J, Kim OJ, Panova I, Symanowski JT, Mahalingam M, Riker AI, Alani RM, Ryu B. Neuropilin-2 gene expression correlates with malignant progression in cutaneous melanoma. Br J Dermatol. 2014 Aug; 171(2):403-8.View Related Profiles. PMID: 24359286; DOI: 10.1111/bjd.12801;.
     
  6. Cao J, Wan L, Hacker E, Dai X, Lenna S, Jimenez-Cervantes C, Wang Y, Leslie NR, Xu GX, Widlund HR, Ryu B, Alani RM, Dutton-Regester K, Goding CR, Hayward NK, Wei W, Cui R. MC1R is a potent regulator of PTEN after UV exposure in melanocytes. Mol Cell. 2013 Aug 22; 51(4):409-22.View Related Profiles. PMID: 23973372; PMCID: PMC3792490; DOI: 10.1016/j.molcel.2013.08.010;.
     
  7. Ryu B, Hwang S, Alani RM. MicroRNAs as an emerging target for melanoma therapy. J Invest Dermatol. 2013 May; 133(5):1137-9.View Related Profiles. PMID: 23594536; DOI: 10.1038/jid.2012.505;.
     
  8. Yan G, Eller MS, Elm C, Larocca CA, Ryu B, Panova IP, Dancy BM, Bowers EM, Meyers D, Lareau L, Cole PA, Taverna SD, Alani RM. Selective inhibition of p300 HAT blocks cell cycle progression, induces cellular senescence, and inhibits the DNA damage response in melanoma cells. J Invest Dermatol. 2013 Oct; 133(10):2444-52.View Related Profiles. PMID: 23698071; DOI: 10.1038/jid.2013.187;.
     
  9. Liu F, Cao J, Wu J, Sullivan K, Shen J, Ryu B, Xu Z, Wei W, Cui R. Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas. J Invest Dermatol. 2013 Aug; 133(8):2041-9.View Related Profiles. PMID: 23344460; DOI: 10.1038/jid.2013.32;.
     
  10. Ryu B, Moriarty WF, Stine MJ, DeLuca A, Kim DS, Meeker AK, Grills LD, Switzer RA, Eller MS, Alani RM. Global analysis of BRAFV600E target genes in human melanocytes identifies matrix metalloproteinase-1 as a critical mediator of melanoma growth. J Invest Dermatol. 2011 Jul; 131(7):1579-83.View Related Profiles. PMID: 21451543; PMCID: PMC3116059; DOI: 10.1038/jid.2011.65;.
     
Showing 10 of 33 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 33 publications over 18 distinct years, with a maximum of 5 publications in 2001

YearPublications
19941
19951
19961
20002
20015
20022
20034
20041
20051
20072
20081
20101
20112
20134
20141
20151
20171
20182
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Biomarkers
Epigenetics
Melanoma
Metastasis
Therapeutic target discovery
Tumor-microenvironment
Contact for Mentoring:


609 Albany St (J Bldg)
Boston MA 02118
Google Map


Ryu's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department